Last reviewed · How we verify

Latanoprost/Timolol therapy

Aristotle University Of Thessaloniki · FDA-approved active Small molecule

Latanoprost/Timolol therapy is a Prostaglandin analog / Beta-blocker combination Small molecule drug developed by Aristotle University Of Thessaloniki. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension. Also known as: Xalacom.

Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic receptor antagonism.

Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic receptor antagonism. Used for Open-angle glaucoma, Ocular hypertension.

At a glance

Generic nameLatanoprost/Timolol therapy
Also known asXalacom
SponsorAristotle University Of Thessaloniki
Drug classProstaglandin analog / Beta-blocker combination
TargetProstaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1, β2)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors on the ciliary muscle, facilitating drainage of fluid from the eye through the unconventional uveoscleral pathway. Timolol is a non-selective beta-blocker that reduces aqueous humor secretion by the ciliary body. The combination provides additive intraocular pressure-lowering effects through complementary mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Latanoprost/Timolol therapy

What is Latanoprost/Timolol therapy?

Latanoprost/Timolol therapy is a Prostaglandin analog / Beta-blocker combination drug developed by Aristotle University Of Thessaloniki, indicated for Open-angle glaucoma, Ocular hypertension.

How does Latanoprost/Timolol therapy work?

Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic receptor antagonism.

What is Latanoprost/Timolol therapy used for?

Latanoprost/Timolol therapy is indicated for Open-angle glaucoma, Ocular hypertension.

Who makes Latanoprost/Timolol therapy?

Latanoprost/Timolol therapy is developed and marketed by Aristotle University Of Thessaloniki (see full Aristotle University Of Thessaloniki pipeline at /company/aristotle-university-of-thessaloniki).

Is Latanoprost/Timolol therapy also known as anything else?

Latanoprost/Timolol therapy is also known as Xalacom.

What drug class is Latanoprost/Timolol therapy in?

Latanoprost/Timolol therapy belongs to the Prostaglandin analog / Beta-blocker combination class. See all Prostaglandin analog / Beta-blocker combination drugs at /class/prostaglandin-analog-beta-blocker-combination.

What development phase is Latanoprost/Timolol therapy in?

Latanoprost/Timolol therapy is FDA-approved (marketed).

What are the side effects of Latanoprost/Timolol therapy?

Common side effects of Latanoprost/Timolol therapy include Conjunctival hyperemia, Iris pigmentation increase, Eyelash growth (hypertrichosis), Eye irritation/discomfort, Headache, Bradycardia.

What does Latanoprost/Timolol therapy target?

Latanoprost/Timolol therapy targets Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1, β2) and is a Prostaglandin analog / Beta-blocker combination.

Related